WO2015009882A3 - Cyano derivatives and their uses - Google Patents

Cyano derivatives and their uses Download PDF

Info

Publication number
WO2015009882A3
WO2015009882A3 PCT/US2014/046937 US2014046937W WO2015009882A3 WO 2015009882 A3 WO2015009882 A3 WO 2015009882A3 US 2014046937 W US2014046937 W US 2014046937W WO 2015009882 A3 WO2015009882 A3 WO 2015009882A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyano
ethyl
hydrazinecarbonyl
methylguanidine
methylthio
Prior art date
Application number
PCT/US2014/046937
Other languages
French (fr)
Other versions
WO2015009882A2 (en
Inventor
M. Bud Nelson
Dhanalekshmi SAVITHRI
Thiagarajan Balasubramanian
Original Assignee
The Hamner Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Hamner Institutes filed Critical The Hamner Institutes
Publication of WO2015009882A2 publication Critical patent/WO2015009882A2/en
Publication of WO2015009882A3 publication Critical patent/WO2015009882A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds inhibit Nrf2 activity for treatment of mycobacterial infection, granulomatous inflammation, tuberculosis, viral infection, or cancer include 5-((2-(2-cyano-3-methylguanidino)ethylthio)methyl)-1 H-imidazole-4carboxamide; 2-cyano-1-(2-( ( 4-hydrazinecarbonyl)-1 H-im idazol-5-yl)methylthio )ethyl-3-methylguanidine; 5-((2-(2-cyano-3-methylguanidino)ethylthio)methyl)-1 H-imidazole-2-carboxamide; 2-cyano-1-(2-((2-hydrazinecarbonyl)-1 H-imidazol-5-yl)methylthio)ethyl-3-methylguanidine; 2-cyano-1-methyl-3-(2-((4- methyl-1 H-imidazol-5-yl)methylamino)ethylguanidine; 3-( ( 2-(2-cyano-3-m ethylg uan idino) ethylth io) m ethyl)pyrazine-2-carboxamide; 6-( ( 2-(2-cyano-3-m ethylg uan idino) ethylth io) m ethyl)pyrazine-2-carboxamide; 2-cyano-1-(2-( ( 4-hydrazinecarbonyl)pyridine-2-yl) methylthio )ethyl-3-methylguanidine; and 2-cyano-1-(2-( ( 4-hydrazinecarbonyl)pyridine-3-yl) methylthio)ethyl-3-methylguanidine; or a pharmaceutically acceptable salt thereof.
PCT/US2014/046937 2013-07-18 2014-07-17 Cyano derivatives and their uses WO2015009882A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361847630P 2013-07-18 2013-07-18
US61/847,630 2013-07-18
US201361891956P 2013-10-17 2013-10-17
US61/891,956 2013-10-17
US201361908215P 2013-11-25 2013-11-25
US61/908,215 2013-11-25
US201462025049P 2014-07-16 2014-07-16
US62/025,049 2014-07-16

Publications (2)

Publication Number Publication Date
WO2015009882A2 WO2015009882A2 (en) 2015-01-22
WO2015009882A3 true WO2015009882A3 (en) 2015-11-12

Family

ID=52346842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/046937 WO2015009882A2 (en) 2013-07-18 2014-07-17 Cyano derivatives and their uses

Country Status (1)

Country Link
WO (1) WO2015009882A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
CN114394939A (en) * 2022-01-27 2022-04-26 河北科技大学 Synthesis method of cimetidine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5541212A (en) * 1994-01-10 1996-07-30 Metatron, Inc. Use of cimetidine for the control of retrovirus infections
US20020077343A1 (en) * 1998-11-17 2002-06-20 David S. Garvey H2 receptor antagonist compounds in combination with nitric oxide donors, compostions and methods of use
US20070281906A1 (en) * 2001-12-06 2007-12-06 Dalton James T Selective androgen receptor modulators for treating diabetes
US20080274104A1 (en) * 2005-02-10 2008-11-06 Arlinghaus Ralph B Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5541212A (en) * 1994-01-10 1996-07-30 Metatron, Inc. Use of cimetidine for the control of retrovirus infections
US20020077343A1 (en) * 1998-11-17 2002-06-20 David S. Garvey H2 receptor antagonist compounds in combination with nitric oxide donors, compostions and methods of use
US20070281906A1 (en) * 2001-12-06 2007-12-06 Dalton James T Selective androgen receptor modulators for treating diabetes
US20080274104A1 (en) * 2005-02-10 2008-11-06 Arlinghaus Ralph B Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics

Also Published As

Publication number Publication date
WO2015009882A2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
EP3889153A4 (en) Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
EP3991731A4 (en) Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
MX2022013950A (en) 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
PH12018500638A1 (en) 2-(het)aryl-substituted condensed bicyclic heterocyclic derivatives as pest control agents
IL272444B (en) Phenyl and heteroaryl derivatives of (1-substituted-piperidin-4- yl)urea, salts thereof and their use for treatment of diseases
MX2015005949A (en) Antiviral azasugar-containing nucleosides.
UA122781C2 (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents
MX2017000305A (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents.
MX2017010124A (en) 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents.
MX2017009880A (en) 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents.
MX2016001011A (en) Substituted quinazolin-4-one derivatives.
BRPI1012331A2 (en) "Active substance combinations nematicides, insecticides and acaricides comprising pyridyl ethylbenzamide and insecticides."
WO2014188178A9 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
WO2008130021A3 (en) Heterocyclic hydrazide compound and pesticidal use of the same
WO2011133521A3 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
MX2016012448A (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents.
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
WO2011005052A8 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
EP2583962A4 (en) Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient
MX2016005324A (en) Pesticidal compositions and related methods.
WO2015009882A3 (en) Cyano derivatives and their uses
EP3470415A4 (en) 5-membered heterocycle fused with [3,4-d]pyridazinone, and manufacturing method, pharmaceutical composition, and application thereof
CY1119483T1 (en) THERAPEUTIC PARTY FOR ANXIETY DISORDERS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14826082

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14826082

Country of ref document: EP

Kind code of ref document: A2